AZTR Quote, Financials, Valuation and Earnings

Altimmune, Inc. has a net margin of 23.36% compared to Azitra, Inc.'s net margin of -105223.08%. Azitra, Inc.'s return on equity of -297.45% beat Altimmune, Inc.'s return on equity of -52.59%.

Azitra, Inc. has a consensus price target of $1.35, signalling upside risk potential of 475.69%. On the other hand Altimmune, Inc. has an analysts' consensus of $18.00 which suggests that it could grow by 439.73%. Given that Azitra, Inc. has higher upside potential than Altimmune, Inc., analysts believe Azitra, Inc. is more attractive than Altimmune, Inc..

Azitra, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Altimmune, Inc. has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.693%.

Azitra, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Altimmune, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Azitra, Inc. pays -- of its earnings as a dividend. Altimmune, Inc. pays out -- of its earnings as a dividend.

Azitra, Inc. quarterly revenues are --, which are smaller than Altimmune, Inc. quarterly revenues of $26K. Azitra, Inc.'s net income of -$2.2M is higher than Altimmune, Inc.'s net income of -$27.4M. Notably, Azitra, Inc.'s price-to-earnings ratio is -- while Altimmune, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azitra, Inc. is 6.94x versus 7,057.52x for Altimmune, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Annovis Bio, Inc. has a net margin of 23.36% compared to Azitra, Inc.'s net margin of --. Azitra, Inc.'s return on equity of -297.45% beat Annovis Bio, Inc.'s return on equity of -176.59%.

Azitra, Inc. has a consensus price target of $1.35, signalling upside risk potential of 475.69%. On the other hand Annovis Bio, Inc. has an analysts' consensus of $12.50 which suggests that it could grow by 448.25%. Given that Azitra, Inc. has higher upside potential than Annovis Bio, Inc., analysts believe Azitra, Inc. is more attractive than Annovis Bio, Inc..

Azitra, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Annovis Bio, Inc. has a beta of 1.369, suggesting its more volatile than the S&P 500 by 36.907%.

Azitra, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Annovis Bio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Azitra, Inc. pays -- of its earnings as a dividend. Annovis Bio, Inc. pays out -- of its earnings as a dividend.

Azitra, Inc. quarterly revenues are --, which are smaller than Annovis Bio, Inc. quarterly revenues of --. Azitra, Inc.'s net income of -$2.2M is higher than Annovis Bio, Inc.'s net income of -$9.8M. Notably, Azitra, Inc.'s price-to-earnings ratio is -- while Annovis Bio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azitra, Inc. is 6.94x versus -- for Annovis Bio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Actinium Pharmaceuticals, Inc. has a net margin of 23.36% compared to Azitra, Inc.'s net margin of -5701.11%. Azitra, Inc.'s return on equity of -297.45% beat Actinium Pharmaceuticals, Inc.'s return on equity of -133.63%.

Azitra, Inc. has a consensus price target of $1.35, signalling upside risk potential of 475.69%. On the other hand Actinium Pharmaceuticals, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 410%. Given that Azitra, Inc. has higher upside potential than Actinium Pharmaceuticals, Inc., analysts believe Azitra, Inc. is more attractive than Actinium Pharmaceuticals, Inc..

Azitra, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Actinium Pharmaceuticals, Inc. has a beta of -0.213, suggesting its less volatile than the S&P 500 by 121.341%.

Azitra, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Azitra, Inc. pays -- of its earnings as a dividend. Actinium Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Azitra, Inc. quarterly revenues are --, which are smaller than Actinium Pharmaceuticals, Inc. quarterly revenues of $90K. Azitra, Inc.'s net income of -$2.2M is higher than Actinium Pharmaceuticals, Inc.'s net income of -$5.1M. Notably, Azitra, Inc.'s price-to-earnings ratio is -- while Actinium Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azitra, Inc. is 6.94x versus 339.83x for Actinium Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

BioAtla, Inc. has a net margin of 23.36% compared to Azitra, Inc.'s net margin of -96.24%. Azitra, Inc.'s return on equity of -297.45% beat BioAtla, Inc.'s return on equity of -567.84%.

Azitra, Inc. has a consensus price target of $1.35, signalling upside risk potential of 475.69%. On the other hand BioAtla, Inc. has an analysts' consensus of $10.00 which suggests that it could grow by 7568.71%. Given that BioAtla, Inc. has higher upside potential than Azitra, Inc., analysts believe BioAtla, Inc. is more attractive than Azitra, Inc..

Azitra, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioAtla, Inc. has a beta of 1.218, suggesting its more volatile than the S&P 500 by 21.831%.

Azitra, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioAtla, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Azitra, Inc. pays -- of its earnings as a dividend. BioAtla, Inc. pays out -- of its earnings as a dividend.

Azitra, Inc. quarterly revenues are --, which are smaller than BioAtla, Inc. quarterly revenues of --. Azitra, Inc.'s net income of -$2.2M is higher than BioAtla, Inc.'s net income of -$15.8M. Notably, Azitra, Inc.'s price-to-earnings ratio is -- while BioAtla, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Azitra, Inc. is 6.94x versus 3.84x for BioAtla, Inc.. Usually stocks with elevated PS ratios are considered overvalued.